Immunodiagnosis of Cancer
Dr D Thomson (Chester Beatty Research Institute, Fulham Road, London SW3) The Carcinoembryonic Antigen (CEA) Radioimmunoassay Recent studies facilitated by improved immunological methods have permitted the detection of tumour-associated substances and tumour-specific antigens. The relevance of these new developments to the clinician is the possibility of exploiting these techniques to detect minute amounts of such constituents in the blood for the early diagnosis and management of cancer. This paper will review, therefore, the development of a radioimmunoassay for the carcinoembryonic antigen in the sera of patients with digestive system cancer and consider its clinical application.
The term carcinoembryonic antigen (CEA) was introduced by Gold & Freedman (1965a, b) to designate a constituent found in all adenocarcinomas of the human digestive system, but normally only present in embryonic and feetal digestive tissues in the first two trimesters of gestation. CEA is a large protein-polysaccharide molecule of consistent chemical and physicochemical properties (Krupey et al. 1967 (Krupey et al. , 1968 . Furthermore, immunofluorescence studies (Gold et al. 1968 ) and ultrastructural studies (Gold et al. 1970) have shown that CEA is primarily localized to the glycocalyx, a cell component lying even further to the periphery than the trilaminar plasma membrane.
Serological studies revealed the presence of macroglobulin antibodies to CEA in the majority of pregnant women and in 70% of patients with non-metastatic digestive tract cancer (Gold 1967) . Once the tumour had metastasized, however, serum samples invariably lacked demonstrable anti-CEA activity. It was originally postulated that the large mass of tumour served as an anti-body 'sink', adsorbing the anti-CEA antibodies (Gold 1967) . Later a second possibility was put forward, that the tumour tissues might release CEA directly into the circulation, complexing all the available anti-CEA antibody (Thomson et al. 1969 ). To confirm this second hypothesis a study was undertaken to develop a radioimmunoassay for the detection of circulating CEA in th2 sera of patients with digestive tract cancer (Thomson etal. 1969) .
A radioinmmunoassay, based on the principle of coprecipitation-inhibition, was devised for the detection of CEA in the circulation. The assay had reproducibility and a sensitivity of 2'5 ng CEA per ml. A double-blind study was performed for the presence of CEA in sera of 200 patients suffering from widely varying conditions. The apparent specificity of the assay was borne out by the fact that CEA was not detected in any serum obtained from the 20 patients with noncancerous diseases of the digestive system, the 17 patients with non-enteric cancer or the 23 with non-enteric non-neoplastic conditions.
With one exception, every patient harbouring cancer of either colonic or rectal origin was found to have detectable levels of circulating CEA. In patients with metastatic colonic or rectal cancer high levels of CEA were invariably found. Notably, detectable CEA was found in only 10 % of patients with cancers of other digestive system organs, most of whom had metastatic spread. No pregnant women had detectable circulating CEA. Although the antigen is present in all adenocarcinomas of the digestive system and in feetal digestive organs in the first two trimesters, the highest tissue concentrations of CEA are found in lower bowel cancers. This probably accounts for the consistent detection of serum CEA only in patients with bowel cancer at the initial level of sensitivity of the assay.
Using an improved version of our own assay, Moore et al. (1971) examined CEA levels in sera.
While confirming our findings in relation to the colon, they found other important differences. For the first time, CEA was detected in patients with non-enteric cancer by means of the CEA radioimmunoassay of sera. Moreover, as yet unexplained positive results occurred in patients with advanced alcoholic cirrhosis, pancreatitis and chronic renal failure in the absence of cancer.
More recently LoGerfo et al. (1971) , employing a zirconyl phosphate gel method of CEA radioimmunoassay, found circulating antigen in 88 out of 101 patients with colonic cancer. In contrast to our original results, nearly 80% of patients with upper digestive tract cancer and over 50% of patients with non-enteric cancer had detectable circulating CEA. These findings clearly indicate that a CEA-like antigen appears in the serum of patients with non-entodermally derived cancer. In 299 patients without apparent neoplasia, 11 false positive results were recorded; interestingly, all these occurred in patients over 51 years, an age group at great risk of occult neoplasms. Subsequent follow up has in fact shown the presence of occult neoplasia in 2 of these patients. In addition, circulating CEA was found in patients with active ulcerative colitis without neoplasia. In this condition, where there is a known predilection to develop colonic cancer, it is important to determine whether the elevated levels of CEA have any clinical significance. For example, does detectable CEA differentiate between those who will eventually develop colonic cancer and those who will remain cancer-free ? To date, all published studies have been primarily concerned with defining the assay's specificity. As yet, no detailed reports have appeared on the value of the assay as a diagnostic tool or as a monitor in patient management. Nevertheless, the potential diagnostic value of the CEA assay is illustrated by case histories previously reported (Thomson 1971) . In these particular and selected clinical problems, the assay added a new dimension to the early detection of cancer when the physician dealt with the whole patient and in the context of all other information.
In our original study, we found that in patients with metastatic cancer circulating CEA remained elevated postoperatively, whereas, in patients with apparently localized tumours, resection of the lesion was accompanied by a fall in serum CEA to undetectable levels (Thomson et al. 1969 ). By monitoring the levels of circulating CEA after tumour resection, an early indication of regrowth as reflected by a rising CEA titre may be obtained and this should stimulate further therapeutic endeavours at a more amenable time.
At present there are two major drawbacks which make the assay unsuitable for general routine large-scale screening. First, the percentage of unexplained positives, although small, would represent an intolerable burden on medical facilities. Secondly, there is as yet no evidence that a large number of early, curable cases would be discovered. The lack of tumour specificity may be considered a major fault. However, this may be circumvented either by developing assays of different specificities or by detecting CEA in secretions from specific organ systems, such as urine, fices and sputum.
In summary, the CEA radioimmunoassay represents the first potentially useful tool for large-scale immunodiagnosis of cancer by the demonstration of a circulating tumour-associated antigen. The ultimate role of the CEA assay in clinical medicine, however, awaits a wider experience.
